Overview of R2 Regimen for Relapsed Follicular Lymphoma

Video

Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R<sup>2</sup> regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br /> &nbsp;

Andre Goy, MD, chief, division of lymphoma, chairman and director, John Theurer Cancer Center, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide (Revlimid) plus rituximab (Rituxan), also known as the R2regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.

In this patient population, rituximab monotherapy was standard treatment, but this was not an appealing option for older patients. The data support R2

Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
A panel of 3 experts on GVHD
A panel of 3 experts on GVHD
Related Content
Positive Topline Data With Nana-val in EBV+ PTCL

Positive Topline Data With Nana-val in EBV+ PTCL

April 16th 2024
Article

Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

April 11th 2024
Article

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

Read More

The Allina Health Approach to Genomic Testing for Cancer

The Allina Health Approach to Genomic Testing for Cancer

April 11th 2024
Article

In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.

Read More